Pediatrics 2006 Nov; 118(5): 2135–45PubMedCrossRef 23. Vadimezan molecular weight Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007 Mar; 26(3): 201–9PubMedCrossRef 24. Giuliano AR, Palefsky JM, Goldstone selleck chemical S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection
and disease in males. N Engl J Med 2011 Feb; 354(5): 401–411. Plus supplementary material available from URL: http://www.nejm.org/doi/full/10.1056/NEJMoa0909537 [Accessed 2011 Feb 4]CrossRef 25. US FDA. Clinical review of biologics license application supplement STN# 125126/1297.0: male indication for GARDASIL [online]. Available from URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM190977.pdf
[Accessed 2010 Jun 1] 26. Vesikari T, Van Damme P, Lindblad N, et al. An open-label, randomized, multicenter check details study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 2010 Apr; 29(4): 314–8PubMed 27. Reisinger KS, Block SL, Collins-Ogle M, et al. Safety, Thiamet G tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics 2010; 125(6): 1142–51PubMedCrossRef 28. Arguedas A, Soley C, Loaiza C, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents
concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010 Apr 19; 28(18): 3171–9PubMedCrossRef 29. Wheeler CM, Bautista OM, Tomassini JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008 Jan 30; 26(5): 686–96PubMedCrossRef”
“1. Introduction Rotavirus gastroenteritis (RVGE) is the most common cause of severe diarrhea among infants and young children aged <5 years in developed and developing countries.[2–4] Symptoms can range from mild watery diarrhea to severe diarrhea with forceful vomiting, abdominal distress, and fever, which can lead to serious complications including dehydration, electrolyte imbalance, seizures, and death.